| Formula |
C12H15N2O |
C38H56N4O9 |
C24H32O5 |
C24H34O4 |
C18H26ClN3 |
| Molecular weight |
203.26 g/mol |
712.87 g/mol |
400.51 g/mol |
386.52 g/mol |
319.87 g/mol |
| Num. heavy atoms |
15 |
51 |
29 |
28 |
22 |
| Num. arom heavy atoms |
9 |
6 |
6 |
6 |
10 |
| Fractions Csp3 |
0.33 |
0.76 |
0.79 |
0.79 |
0.50 |
| Num. rotable bonds |
0 |
18 |
1 |
1 |
8 |
| Num. H-bond acceptors |
2 |
10 |
5 |
4 |
2 |
| Num. H-bond donors |
2 |
6 |
2 |
2 |
1 |
| Molar Refractivity |
66.18 |
190.16 |
108.86 |
109.86 |
97.41 |
| TPSA |
36.02 Ų |
217.57 Ų |
83.20 Ų |
70.67 Ų |
28.16 Ų |
|
LIPOPHILICITY
|
| Log P
olw (ILOGP) |
-1.27 |
3.47 |
3.27 |
3.34 |
3.95 |
| Log P
olw (XLOGP3) |
1.64 |
3.23 |
2.50 |
3.2 |
4.63 |
| Log P
olw (WLOGP) |
1.62 |
4.10 |
3.37 |
4.24 |
4.62 |
| Log P
olw (MLOGP) |
-2.19 |
2.12 |
2.75 |
3.58 |
3.20 |
| Log P
olw (SILICOS-IT) |
2.15 |
4.89 |
3.82 |
3.99 |
4.32 |
| Consensus Log P olw |
0.39 |
3.56 |
3.14 |
3.67 |
4.15 |
|
WATER SOLUBILITY
|
| Log S (ESOL) |
-2.58 |
-5.19 |
-3.99 |
-4.35 |
-4.55 |
| Solubility |
5.38e-01 mg/mL; 2.65e-03 mol/L |
4.56e-03 mg/mL; 6.40e-06 mol/L |
4.14e-02 mg/mL; 1.03e-04 mol/L |
1.75e-02 mg/mL; 4.52e-05 mol/L |
9.05e-03 mg/mL; 2.83e-05 mol/L |
| Class |
Soluble |
Moderately soluble |
Soluble |
Moderately soluble |
Moderately soluble |
| Log S (Ali) |
-2.01 |
-7.47 |
-3.89 |
-4.36 |
-4.95 |
| Solubility |
1.99e+00 mg/mL; 9.78e-03 mol/L |
2.40e-05 mg/mL; 3.37e-08 mol/L |
5.13e-02 mg/mL; 1.28e-04 mol/L |
1.70e-02 mg/mL; 4.41e-05 mol/L |
3.61e-03 mg/mL; 1.13e-05 mol/L |
| Class |
Soluble |
Poorly soluble |
Soluble |
Moderately soluble |
Moderately soluble |
| Log S (SILICOS-IT) |
-4.09 |
-7.46 |
-4.73 |
-5.2 |
-6.92 |
| Solubility |
1.63e-02 mg/mL; 8.04e-05 mol/L |
2.45e-05 mg/mL; 3.44e-08 mol/L |
7.42e-03 mg/mL; 1.85e-05 mol/L |
3.68e-03 mg/mL; 9.53e-06 mol/L |
3.86e-05 mg/mL; 1.21e-07 mol/L |
| Class |
Moderately soluble |
Poorly soluble |
Moderately soluble |
Moderately soluble |
Poorly soluble |
|
PHARMACOKINETICS
|
| GI absorption |
High |
Low |
High |
High |
High |
| BBB permeant |
Yes |
No |
No |
Yes |
Yes |
| P-gp substrate |
Yes |
Yes |
Yes |
Yes |
No |
| CYP1A2 inhibitor |
Yes |
No |
No |
No |
Yes |
| CYP2C19 inhibitor |
No |
No |
No |
No |
No |
| CYP2C9 inhibitor |
No |
No |
No |
No |
No |
| CYP2D6 inhibitor |
No |
No |
Yes |
No |
Yes |
| CYP3A4 inhibitor |
No |
Yes |
No |
No |
Yes |
| Log Kp (skin permeation) |
-6.38 cm/s |
-8.36 cm/s |
-6.97 cm/s |
-6.39 cm/s |
-4.96 cm/s |
|
DRUGLIKENESS
|
| Lipinski |
Yes; 0 violation |
No; 3 violations: MW>500, NorO>10, NHorOH>5 |
Yes; 0 violation |
Yes; 0 violation |
Yes; 0 violation |
| Ghose |
Yes |
No; 3 violations: MW>500, NorO>10, NHorOH>5 |
Yes |
Yes |
Yes |
| Veber |
Yes |
No; 2 violations: Rotors>10, TPSA>140 |
Yes |
Yes |
Yes |
| Egan |
Yes |
No; 1 violation: TPSA>131.6 |
Yes |
Yes |
Yes |
| Muegge |
Yes |
No; 4 violations: MW>600, TPSA>150, Rotors>15, H-don>5 |
Yes |
Yes |
Yes |
| Biovailability Score |
0.55 |
0.17 |
0.55 |
0.55 |
0.55 |
|
MEDICINAL CHEMISTRY
|
| PAINS |
0 alert |
0 alert |
0 alert |
0 alert |
0 alert |
| Brenk |
1 alert quaternary_nitrogen_2 |
3 alerts: Three-membered_heterocycle, imine_1, imine_2 |
1 alert: Three-membered_heterocycle |
0 alert |
0 alert |
| Leandlikeness |
No; 1 violation: MW<250 |
No; 2 violations: MW>350, Rotors>7 |
No; 1 violation: MW>350 |
No; 1 violation: MW>350 |
No; 2 violations: Rotors>7, XLOGP3>3.5 |
| Synthetic accessibility |
2.14 |
7.71 |
6.07 |
5.56 |
2.76 |
